Relatively speaking how will different groups fair this summer? Specifically how will groups such as LevFin, HC, and FIG perform relative to the others? I am asking with regards to this upcoming summer and into 2021 if you think it's applicable.
| +146 | How to stop feeling like shit for not making it in IB? | 55 | 5h | |
| +109 | If Tik Tok is forced to sell, what banks do you think would be involved in the deal? | 54 | 23m | |
| +68 | Updated LA Banking Scene (2024) | 50 | 2s | |
| +38 | Ranking banks that went under | 20 | 2h | |
| +34 | Burnt Out M&A ASO | 18 | 2s | |
| +32 | A strategy for SA applicants late to the game like myself | 15 | 7h | |
| +31 | UBS Actual Buyside Exits 2024 Post-Integration | 9 | 3d | |
| +31 | Recruiting in the Fall | 6 | 5s | |
| +29 | Relevance of A-Levels for U.K. London recruiting | 21 | 13h | |
| +26 | Series 79 Help / Tips to Pass The First Attempt | 11 | 1d |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Lev Fin and Consumer most likely, although if the bank has an RX division, all groups will be pretty busy
NA
Any thoughts on healthcare?
Friends at EB said they're super busy but that could be because the bank has RX
Still active, probably not much less than normal. Have not heard of any cuts or shocking declining deal flow from any banks for this group. I think March was tough for everyone but the rebound was fairly easy and expected.
Why do you anticipate Consumer groups will be busy?
I work in consumer M&A and it's been pretty fucked but starting to improve a bit. Businesses that have an e-commerce angle, are in food & bev (through retail) and consumer health are doing solid and will come to market soon depending on debt market conditions. Investors want to put money to work so it's really a question of leverage and if good businesses are going to take a multiple hit because of COVID.
However, most other parts of consumer have been hit hard and are going to wait 6-12 months to see where they are at before they consider an exit. A lot of them will want a full year of post-COVID financials so they don't need to defend some crazy adjustments (outside of the normal aggressive add-backs we apply). Obviously, they also want the business to be stable going into a sale process.
What about FIG?
Curious about folks thoughts on this as well. Smaller community banks are going to get crushed in the coming months as a good amount of small / medium sized local businesses inevitably default, not to mention community banks in the South that are heavily exposed to O&G... wonder if this will spur some M&A by larger banks.
For insurance, there will be a ton of corona related claims, which can only hurt profitability. I wonder if this would increase IB activity as a FIG banker or decrease it?
What about Tech groups?
Maybe surprisingly not as bad as you'd think - many tech companies are on recurring revenue models and e-commerce is looking particularly rosy in this environment. Liquidity may be an issue if they're burning a lot of cash and can't issue IG grade debt.
Don’t work in a tech group but have a lot of friends at software companies. They are seeing a lot of customer churn with subscriptions being cancelled / frozen, no new deals, etc. For startups that were relying on series funding to drive growth - there will definitely be near-term liquidity constraints & layoffs which will put a hamper on overall growth trajectory and future funding
Which would be a better product group to be in, M&A or Levfin? Would it be better to be in a product group or an industry group?
Lev Fin for sure will have a ton of work this summer (late summer) and will get affected due to the new low interest rates- companies will be doing a ton of refis and trying to raise debt at these low rates. M&A will be slow for a while until probably September. Of course RX will have a ton of work as well for the EBs
Don't agree - HY / non-IG financing relies a lot more on spreads than the underlying base rates. A leveraged loan has spreads of several hundred basis points above a reference rate - those spreads have widened more than reference rates have come down. LevFin may take a long time to get going again, depending on what defaults in the space look like. Energy is also a core part of HY issuance and they're not in the best shape as of now. M&A usually has RX roll in under them and companies may potentially be divesting assets to raise capital so I'd say that is for sure a safer bet than LevFin.
To go off of this, are analysts at EBs be getting the same amount/more work? If they work alongside their RX counterparts to advise on reorganizations and divestitures
This is valid. Outlook for levfin probably going to be scary. But speaking with people in a strong levfin group, it seems like depending on the industry/company, there still seems to be robust activity going on.
Maybe the analogy to make is that it can be like RX. Everyone says that RX does well in downturns, but in economic booms "there's always a company that needs to restructure." Likewise, there's probably always a company that wants to try and issue or refi for whatever reason.
LevFins groups are not super busy. Primarily spending time on amendments / cov relief. Fees on those situations are half compared to general underwriting fees.
LevFin will be busy once sponsors feel assets are appropriately priced / sellers come to the realization that their assets are worth lower from pre-covid valuations.
Sponsors also need to account for OID. Secondary lev loan market is ~90. Ideally need it to be in the ~95 zipcode for effective issuance.
Gut feeling -will prob see traditional sponsor activity in late August / September.
Oh okay that makes sense. I was looking at M&A as a comparison because M&A fees dropped like a brick YoY whereas Lev Fin revenue is actually up YoY for places like JPM- at least according to dealogic- have you seen the effects of this increase?
I can confirm HC teams are very busy. Sometimes just because it is the "flavour of the month" given the pandemic. I am seeing a few transactions go through, under the banner of "Healthcare is counter cyclical" or "HC sector is benefitting from this" [Which is not true, at all]
Any insight as to what deal flow will look like for healthcare in the coming months (i.e summer and into the fall)?
I can only speak for EMEA: right now the only deals going through are those that could benefit somehow from Covid-19 situation (Dx, Pharma with potential treatments, hospital sterilisation, medical supplies, etc.) and the PE guys who are circling around publicly-listed companies who tanked (but have good fundamentals). Look, if you are looking for deal flow, go to an M&A team. You can then switch to a sector if you want. If you cannot, TMT, HC and FIG will always have deals right, left and centre.
Sector is definitely not benefiting from covid but I would say it has more economic resistance than others.
How is DCM doing in all of this?
Tale of two cities - IG = booming while the window was open (last week especially), HY= free time to brush up your resume.
They are killing it. Most money center BB are generating majority of their revenue from DCM (IG)
can anyone comment on industrials and the specific verticals?
Non molestiae ut in. Temporibus perspiciatis modi quis illum necessitatibus temporibus repellat. Ut qui velit facilis perferendis.
Et totam est et voluptatem eveniet eaque placeat. Quidem hic dicta officiis alias aut nihil qui. Corrupti nisi alias porro ut error sit. At possimus ipsam sed occaecati.
Nihil ut non porro eum nostrum dolores quae. Quam iure illum eligendi. Omnis sed vel exercitationem quae pariatur minima ducimus. Ad dolor sint sed blanditiis. Delectus dicta at sapiente reprehenderit.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Dolorem quo dicta itaque quo quasi eius sint ratione. Suscipit reprehenderit magnam ratione libero. Alias similique iusto minus corporis sit. Asperiores quos est maiores sed vel similique nesciunt voluptatem.
Ut molestiae dolores debitis expedita voluptatem ad earum. Aut ut hic soluta consequatur. Quae reprehenderit et similique non sit ut nemo iure.
Maiores nesciunt non aut doloribus corrupti. Ducimus est odit harum odio.
Esse veniam minima nam unde illo. Dolorem soluta sed et ullam nisi facilis placeat. Unde eum recusandae autem quas. Ex enim nulla aut et distinctio incidunt doloremque.